高强度聚焦超声联合胶束纳米颗粒包裹表柔比星K-912的首例人体安全性与有效性研究:一种治疗难治性腹部肿瘤的新型声动力疗法
单中心前瞻性探索性临床试验评估新型触发脉冲高强度聚焦超声设备MS-2联合胶束纳米颗粒包裹表柔比星K-912声动力治疗不可切除难治性腹部肿瘤的安全性及有效性。12例IV期胰腺癌(11例)和胆管细胞癌(1例)患者按3+3设计递增HIFU功率(75和150 W,1 MHz)和K-912剂量(30和80 mg/m2),共4个队列。结果未观察到≥3级不良事件,认为可耐受的HIFU功率和K-912剂量分别为150 W和80 mg/m2,肿瘤完全和部分凝固性坏死率分别为33.3%和41.7%,主要疾病控制率为66.7%,33.3%患者疼痛改善。
要点
- HIFU功率150 W和K-912剂量80 mg/m2被认为可耐受,试验中未观察到≥3级不良事件。
- 肿瘤完全和部分凝固性坏死率分别为33.3%和41.7%,主要疾病控制率为66.7%。
- 33.3%患者疼痛改善,未见与K-912相关的不良事件。
核心结论
- 使用MS-2和K-912的声动力治疗在晚期腹部肿瘤患者中安全且耐受良好,并显示出有前景的初步临床活性。
研究设计与样本
- 单中心前瞻性探索性临床试验,共12例患者(IV期胰腺癌11例,胆管细胞癌1例),HIFU功率(75和150 W,1 MHz)和K-912剂量(30和80 mg/m2)按3+3设计递增,共4个队列,每队列3例;K-912在HIFU治疗前一天静脉给药。
关键影像表现/征象
- 平均超声照射时间为22.3 min,总照射次数为17.4次。
- 肿瘤完全和部分凝固性坏死率分别为33.3%和41.7%。
- 主要疾病控制率为66.7%,33.3%患者疼痛改善。
诊断标准与关键数值
- 认为可耐受的HIFU功率为150 W,K-912剂量为80 mg/m2。
临床应用与阅片要点
- 本研究表明使用MS-2和K-912的声动力治疗在晚期腹部肿瘤患者中安全且耐受良好,并显示出有前景的初步临床活性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Aims of this first-in-human clinical trial were to evaluate the safety and efficacy of sonodynamic therapy (SDT) using a newly developed trigger pulse high-intensity focused ultrasound (HIFU) device, MS-2, and micellar nanoparticle-encapsulated epirubicin, K-912, in patients with unresectable refractory abdominal cancers.
METHODS: This was a single center prospective exploratory clinical trial. The HIFU sonication power (75 and 150 W at 1 MHz) and K-912 dose (30 and 80 mg/m2) were increased incrementally (4 cohorts) according to 3+3 design. Each cohort consisted of three patients. K-912 was administered intravenously one day before HIFU treatment.
RESULTS: A total of 12 patients with stage IV pancreatic cancer (n = 11) and cholangiocellular carcinoma (n = 1) completed the SDT. The mean sonication time and total number of sonication was 22.3 min and 17.4 shots, respectively. No adverse events of grade ≥3 were observed during the trial up to 30 days after HIFU treatment. No adverse events related to K-912 were noted. The HIFU sonication power and K-912 dose considered to be tolerable were 150 W and 80 mg/m2, respectively. The rate of complete and partial tumor coagulative necrosis was 33.3% and 41.7%, respectively. The primary disease control rate was 66.7%. Pain was improved in 33.3% of patients.
CONCLUSIONS: This trial demonstrated that SDT using MS-2 and K-912 was safe and well tolerated in patients with advanced abdominal tumors and showed promising preliminary clinical activity.
引用
- Muragaki Y, Sofuni A, Okamoto J, et al. First-in-Human Safety and Efficacy Study on Combination of High-Intensity Focused Ultrasound Sonication and Micellar Nanoparticle-Encapsulated Epirubicin, K-912: A Novel Sonodynamic Therapy for the Treatment of Refractory Abdominal Cancers. Ultrasound Med Biol. 2025. PMID: 41318252. doi:10.1016/j.ultrasmedbio.2025.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。